Literature DB >> 28627672

Inhibition of Skp2 suppresses the proliferation and invasion of osteosarcoma cells.

Lu Ding1, Rong Li2, Xiaoping Han3, Yubo Zhou4, Hua Zhang3, Yong Cui3, Wu Wang3, Jingping Bai1.   

Abstract

Osteosarcoma (OS) is a common bone tumor that mainly affects children and young adults. S-phase kinase‑associated protein 2 (Skp2) has been characterized to play a critical oncogenic role in a variety of human malignancies. However, the biological function of Skp2 in OS remains largely obscure. In the present study, we elucidated the role of Skp2 in cell growth, cell cycle, apoptosis and migration in OS cells. We found that depletion of Skp2 inhibited cell growth in both MG-63 and SW 1353 cells. Moreover, we observed that depletion of Skp2 triggered cell apoptosis in two OS cell lines. Furthermore, downregulation of Skp2 induced cell cycle arrest in the G0/G1 phase in OS cells. Notably, our wound healing assay results revealed that inhibition of Skp2 suppressed cell migration in OS cells. Invariably, our western blot results demonstrated that depletion of Skp2 in OS cells inhibited activation of pAkt and increased p27 expression in OS cells, suggesting that Skp2 exerted its oncogenic function partly through the regulation of Akt and p27. Our findings revealed that targeting Skp2 could be a promising therapeutic strategy for the treatment of OS.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28627672     DOI: 10.3892/or.2017.5713

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  7 in total

Review 1.  Targeting the untargetable: RB1-deficient tumours are vulnerable to Skp2 ubiquitin ligase inhibition.

Authors:  Pranav Gupta; Hongling Zhao; Bang Hoang; Edward L Schwartz
Journal:  Br J Cancer       Date:  2022-06-25       Impact factor: 9.075

2.  The antioncogenic effect of Beclin-1 and FOXP3 is associated with SKP2 expression in gastric adenocarcinoma.

Authors:  Hyung Kyung Kim; Kyu Yeoun Won; Sang-Ah Han
Journal:  Medicine (Baltimore)       Date:  2021-08-20       Impact factor: 1.817

3.  S-phase kinase-associated protein 2 is involved in epithelial-mesenchymal transition in methotrexate-resistant osteosarcoma cells.

Authors:  Lu Ding; Chengwei Wang; Yong Cui; Xiaoping Han; Yang Zhou; Jingping Bai; Rong Li
Journal:  Int J Oncol       Date:  2018-03-29       Impact factor: 5.650

4.  WWP2 regulates pathological cardiac fibrosis by modulating SMAD2 signaling.

Authors:  Huimei Chen; Aida Moreno-Moral; Francesco Pesce; Nithya Devapragash; Massimiliano Mancini; Ee Ling Heng; Maxime Rotival; Prashant K Srivastava; Nathan Harmston; Kirill Shkura; Owen J L Rackham; Wei-Ping Yu; Xi-Ming Sun; Nicole Gui Zhen Tee; Elisabeth Li Sa Tan; Paul J R Barton; Leanne E Felkin; Enrique Lara-Pezzi; Gianni Angelini; Cristina Beltrami; Michal Pravenec; Sebastian Schafer; Leonardo Bottolo; Norbert Hubner; Costanza Emanueli; Stuart A Cook; Enrico Petretto
Journal:  Nat Commun       Date:  2019-08-09       Impact factor: 14.919

Review 5.  Emerging Roles of SKP2 in Cancer Drug Resistance.

Authors:  Ting Wu; Xinsheng Gu; Hongmei Cui
Journal:  Cells       Date:  2021-05-10       Impact factor: 6.600

6.  MiR-506 exerts antineoplastic effects on osteosarcoma cells via inhibition of the Skp2 oncoprotein.

Authors:  Lu Ding; Rongxin Sun; Qi Yan; Chengwei Wang; Xiaoping Han; Yong Cui; Rong Li; Jiwen Liu
Journal:  Aging (Albany NY)       Date:  2021-02-17       Impact factor: 5.682

7.  Down-regulation of Skp2 expression inhibits invasion and lung metastasis in osteosarcoma.

Authors:  Yidan Zhang; Yoav S Zvi; Brian Batko; Nikolas Zaphiros; Edmond F O'Donnell; Jichuan Wang; Kenji Sato; Rui Yang; David S Geller; Pratistha Koirala; Wendong Zhang; Xiuquan Du; Sajida Piperdi; Yang Liu; Deyou Zheng; Michael Roth; Jonathan Gill; Jinghang Zhang; Tingting Ren; Richard Gorlick; Xiaolin Zi; Bang H Hoang
Journal:  Sci Rep       Date:  2018-09-24       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.